Biomagnetics Diagnostics Meets Integrated Optical Biosensor Building Team for New Product Development

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, Cholera and malaria detection, and other innovative technologies, today announced CEO Clayton Hardman attended a series of meetings on the important topic of diagnosing and managing tuberculosis ("TB") with industry leaders from the Centers for Disease Control, the Foundation for New Innovative Diagnostics ("FIND"), the World Health Organization and the University of KwaZulu-Natal, South Africa and others, at a Symposium hosted by Los Alamos National Laboratory.

While at the Global Tuberculosis Surveillance Workshop held this month in Santa Fe, New Mexico, Biomagnetics Diagnostics Corp. met with the engineering team from Los Alamos that built the bench-top prototype unit of its Integrated Optical Biosensor ("IOBS") for the detection of TB. As a result of these meetings, development of the "IOBS" moved forward as the engineers at Los Alamos agreed to meet with Lathrop Engineering to fabricate a production model and miniaturization unit of the IOBS. With the assistance of LANL the Company also made arrangements to collaborate with other leaders in the field to conduct validation studies on the IOBS device and TB assay upon finalization, and assist with developing the HIV assay, and assist with clinical trials and approvals.

Additionally, Mr. Hardman is planning to attend further meetings where he expects to gain insights into the current status of tuberculosis related activities, interests and goals at the Center for Disease Control ("CDC"), one of the premier U.S. organizations for the study and containment of prevalent global diseases.

Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. commented, "Attending the Global Tuberculosis Surveillance Workshop sponsored by LANL has been a valuable experience. We are glad to have been a part of this symposium and look forward to working with the alliances to bring the IOBS unit to market."

Source: http://www.biomagneticsbmgp.com/